Search
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedFood and Drug Administration (FDA) for the imaging of lymph nodes with or without scintigraphic imaging. … It may be administered via subcutaneous, intradermal, subareolar, or peritumoral injection, depending on the tutor location and planned injection technique [FDA Label].
Lovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigationalto be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who
Rofecoxib
go.drugbank.com/drugs/DB00533ApprovedWithdrawnRofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras.
Nelarabine
go.drugbank.com/drugs/DB01280ApprovedInvestigational[A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … [A15220] Subsequently, nelarabine was also approved by both Health Canada and European Medicines Agency in 2007 under the trademark name ATRIANCE.[L45874,L45879]
Fitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770] … [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[L15002] The modRNA is formulated in lipid nanoparticles for administration via intramuscular injection in two doses, three weeks apart. … [L15017, L15022] Comirnaty received fast track designation by the U.S. FDA on July 13, 2020.
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older.
Esmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnIt has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.
Zolmitriptan
go.drugbank.com/drugs/DB00315ApprovedInvestigational[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.
Eletriptan
go.drugbank.com/drugs/DB00216ApprovedInvestigationalEletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.